BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26500060)

  • 21. VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations.
    Rechsteiner MP; von Teichman A; Nowicka A; Sulser T; Schraml P; Moch H
    Cancer Res; 2011 Aug; 71(16):5500-11. PubMed ID: 21715564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
    Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
    Anal Cell Pathol (Amst); 2010; 33(3):121-32. PubMed ID: 20978319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus.
    Roos FC; Roberts AM; Hwang II; Moriyama EH; Evans AJ; Sybingco S; Watson IR; Carneiro LA; Gedye C; Girardin SE; Ailles LE; Jewett MA; Milosevic M; Wilson BC; Bell JC; Der SD; Ohh M
    EMBO Mol Med; 2010 Jul; 2(7):275-88. PubMed ID: 20623734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice.
    Wang J; Ma Y; Jiang H; Zhu H; Liu L; Sun B; Pan S; Krissansen GW; Sun X
    J Hepatol; 2011 Aug; 55(2):359-68. PubMed ID: 21168458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression.
    Di Cristofano C; Minervini A; Menicagli M; Salinitri G; Bertacca G; Pefanis G; Masieri L; Lessi F; Collecchi P; Minervini R; Carini M; Bevilacqua G; Cavazzana A
    Am J Surg Pathol; 2007 Dec; 31(12):1875-81. PubMed ID: 18043042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients.
    Fabbri L; Dufies M; Lacas-Gervais S; Gardie B; Gad-Lapiteau S; Parola J; Nottet N; Meyenberg Cunha de Padua M; Contenti J; Borchiellini D; Ferrero JM; Leclercq NR; Ambrosetti D; Mograbi B; Richard S; Viotti J; Chamorey E; Sadaghianloo N; Rouleau M; Craigen WJ; Mari B; Clavel S; Pagès G; Pouysségur J; Bost F; Mazure NM
    Theranostics; 2020; 10(6):2696-2713. PubMed ID: 32194829
    [No Abstract]   [Full Text] [Related]  

  • 31. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
    Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
    Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.
    Kucejova B; Peña-Llopis S; Yamasaki T; Sivanand S; Tran TA; Alexander S; Wolff NC; Lotan Y; Xie XJ; Kabbani W; Kapur P; Brugarolas J
    Mol Cancer Res; 2011 Sep; 9(9):1255-65. PubMed ID: 21798997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of somatic VHL gene mutations in sporadic head and neck paragangliomas in association with activation of the HIF-1α/miR-210 signaling pathway.
    Merlo A; de Quirós SB; de Santa-María IS; Pitiot AS; Balbín M; Astudillo A; Scola B; Arístegui M; Quer M; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2013 Oct; 98(10):E1661-6. PubMed ID: 23902947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma.
    Ruf M; Moch H; Schraml P
    Int J Cancer; 2016 Jul; 139(2):396-403. PubMed ID: 26945902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
    Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
    Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis.
    Myszczyszyn A; Czarnecka AM; Matak D; Szymanski L; Lian F; Kornakiewicz A; Bartnik E; Kukwa W; Kieda C; Szczylik C
    Stem Cell Rev Rep; 2015 Dec; 11(6):919-43. PubMed ID: 26210994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
    Ji SQ; Su XL; Cheng WL; Zhang HJ; Zhao YQ; Han ZX
    Urol Oncol; 2014 Feb; 32(2):153-61. PubMed ID: 23273913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SHARPIN regulates the development of clear cell renal cell carcinoma by promoting von Hippel-Lindau protein ubiquitination and degradation.
    Yin R; Liu S
    Cancer Sci; 2021 Oct; 112(10):4100-4111. PubMed ID: 34339558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.
    Xu J; Wang B; Xu Y; Sun L; Tian W; Shukla D; Barod R; Grillari J; Grillari-Voglauer R; Maxwell PH; Esteban MA
    Oncogene; 2012 Feb; 31(8):1065-72. PubMed ID: 21841824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma.
    Dere R; Perkins AL; Bawa-Khalfe T; Jonasch D; Walker CL
    J Am Soc Nephrol; 2015 Mar; 26(3):553-64. PubMed ID: 25313256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.